Effect of a high-tech autologous immunocyte preparation on the tumor cell microenvironment and survival of rats with C6 glioma (in vivo experimental study)

INTRODUCTION . Glioblastoma (GB) is one of the most lethal human brain tumors. AIM. To study the effect of a preparation of autologous immunocytes with activated TLR/NF-k signaling on the microenvironment of tumor cells (TC) and the survival of rats with C6 glioma. MATERIALS AND METHODS . C6 glioma cells, bone marrow mononuclear cells (BMMC), and outbred Wistar rats were used. Methods: experimental modeling in vivo and in vivo, morphological, immunohistochemical, and enzyme immunoassay. Survival was assessed according to Kaplan – Meier. RESULTS. Ex vivo treatment of mononuclear cells with LPS + dsRNA allows obtaining a high-tech medicinal product (HTMP) characterized by the expression of CD3+ antigens of early activation of B lymphocytes (97.9±7.1 vs. 80.1±6.1 %, P<0.05) and NK cells (91.8±11.1 vs. 72.2±7.7 %, P<0.05), an increase in the number of T-killers in relation to T-suppressor cells (42.8±4.4 vs. 30.5±3.1 %, P<0.05), expression of the early lymphocyte activation antigen CD69 (82.2±18.8 vs. 11.2±2.2, P<0.05), an increase in the content of CD45+ cells (66.3 vs. 42.1%, ) and a decrease in the content of stem cells CD90+ cells (3.3 versus 21.5 %). Transplantation of HTMP into the body of rats with C6 glioma enriches the tumor with markers of CD86+ cells, which is accompanied by an increase in the content of proinflammatory cytokines IL-1, B – IL 6, B – IL18, TNF1. The combination of HTMP and plerixafor increases the survival of experimental animals (74,5 versus 60 days, P<0,0001). CONCLUSION . The complex use of HTMP and plerixafor modifies the OC microenvironment and increases the survival of experimental animals with C6 glioma